Dr. Hal Marcus Weitzbuch, MD, MS

Dr. Weitzbuch practices at Brilliance Dermatology in Calabasas, California.

Dr. Weitzbuch's NPI, 1669629317, was assigned on August 25, 2008. Dr. Weitzbuch graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2008. Dr. Weitzbuch holds California license A 121615.

Dr. Weitzbuch's primary practice is Brilliance Dermatology, at 23501 Park Sorrento, Calabasas, CA 91302 in Los Angeles County. The practice phone is (818) 222-7495.

Dr. Weitzbuch's primary practice is Brilliance Dermatology in Calabasas, California. The medical group on file is Brilliance Dermatology. Dmand AI also links Dr. Weitzbuch to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weitzbuch practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Weitzbuch's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Weitzbuch is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Weitzbuch's licenses on file in 3 states: California, South Dakota and Illinois.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Weitzbuch treats.

CMS data shows 32,073 Medicare services from Dr. Weitzbuch across 38 procedure codes in 2024, for 1,691 Medicare patients. Medicare paid $872,014 for them. Every service was in an office.

CMS counts 1,691 Medicare patients who saw Dr. Weitzbuch in 2024. The largest group is 65 to 74, with 877 patients. 75% of them have high cholesterol, and 63% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Weitzbuch's median patient age at 58, with 57% women.

In 2024, Dr. Weitzbuch wrote 833 Medicare Part D claims for 426 patients. 91% of them were for generic drugs. CMS names the drug for 696 of them, across 21 drugs with 11 or more claims each, at $225,423 in total drug cost. In 2023, CMS named 813 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Weitzbuch for performance year 2024, reported individually. Dr. Weitzbuch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weitzbuch as offering telehealth. CMS counts 4,836 procedures of removal of skin lesions by Dr. Weitzbuch, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Weitzbuch.

CMS Open Payments shows 1,180 general payments to Dr. Weitzbuch from 47 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 77% of the total. Galderma Laboratories, L.P. paid the most, $160,274.

Dmand AI lists 3 awards for Dr. Weitzbuch, most recently ASDS Preceptorship Grant at UCLA in 2011.

Dr. Weitzbuch graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2008. Dr. Weitzbuch is a member of AAD, AMA, ASDS and CMA.

Dr. Weitzbuch is in network with 9 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.